Tempol – Gel

Adamis has a worldwide license to use Tempol for the use of reducing radiation dermatitis in patients undergoing treatment for cancer.

 

Potential Indication: Cancer (Radiation induced dermititis)

A phase 2 radiation dermatitis clinical study has already been successfully completed as well as discussions with the FDA regarding the design of a pivotal phase 3 study.

Radiation therapy is a common treatment for cancer patients. One of the most common side effects of radiation is acute skin reaction (radiation dermatitis) that ranges from a mild rash to severe ulceration. Approximately 85% of patients treated with radiation therapy will experience a moderate-to-severe skin reaction. There are no approved treatments currently for radiation induced dermatitis.